Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

  • End date
    May 15, 2023
  • participants needed
  • sponsor
    Guangzhou Gloria Biosciences Co., Ltd.
Updated on 9 February 2022
metastatic cervical cancer


Patients with recurrent or metastatic cervical cancerand will be treated with GLS-010.


Open, uncontrolled, multi-center, phase II study.

Condition Cervical Cancer
Treatment GLS-010
Clinical Study IdentifierNCT03972722
SponsorGuangzhou Gloria Biosciences Co., Ltd.
Last Modified on9 February 2022


Yes No Not Sure

Inclusion Criteria

Willingness to participate in the clinical trial; completely understanding and knowing about the study and signing the ICF; willingness and capability to comply with the requirements of the study
Female aged from 18 to 75 years (margin included)
Cervical cancer patients with histologically confirmed PD-L1 positive (CPS 1)
Recurrent or metastatic cervical cancer patients who progress after receiving 1 chemotherapy or are resistant to chemotherapy
Based on RECIST 1.1, at least one measurable lesions, i.e. an extranodal lesion 10 mm in the longest diameter of cross-sectional areas or a lymph node lesion 15 mm in the shortest diameter of cross-sectional areas in CT or MRI test
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Life expectancy 12 weeks
Organ and hematopoietic function as defined below
Hemoglobin (HGB) 90 g/L; White blood cell (WBC) 3 X 109/L; Absolute neutrophil
count (ANC) 1.5 X 109/L; Platelets (PLT) 100 X 109/L; Total bilirubin 1.5upper
limit of normal (ULN); AST and ALT 2.5ULN or, for hepatic dysfunction due to
liver metastases, 5ULN; Serum creatinine (Cr) 1.5 X ULN or a creatinine
clearance (CrCl) 50 mL/min; International normalized ratio (INR) or activated
partial thromboplastin time (aPTT)1.5ULN
\. Female patients of childbearing potential should be willing to birth
control after ICF signing, the course of the study, and 5 months after the
last dose of study medication
\. Patients must agree to provide either an archival tumor tissue sample or
fresh biopsy sample for baseline biomarker tissue analyses, including staining
for PD-L1. If archival tissue is not available and the patient does not have
biopsy-accessible tumor lesions, the patient will be excluded

Exclusion Criteria

Prior therapy with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137 or anti-CTLA-4 agent (including Ipilimumab or any other drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior anti-tumor therapy,(including chemotherapy, targeted small molecule therapy , radiotherapy, immunotherapy, mAb therapy) , or treatment with investigational products having not been launched onto the market in China in other clinical trials within 4 weeks prior to the first dose
A past history of allergic reactions attributed to any macromolecular protein preparation/monoclonal antibody, or any other composition of the investigational product
Pregnancy or lactation
Patients with any autoimmune disease and received systemic therapy within 2 years (i.e. corticosteroids or immunosuppressive medications) [i.e.,but not limited to, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and chemotherapy can be included), patients with vitiligo or asthma CR in Childhood, not requiring any intervention in adulthood are permitted to enroll; patients with asthma requiring a bronchiectasis intervention are not permitted to enroll]
Subjects that requires systemic corticosteroids (dose equivalent to or above 10 mg prednisone daily) or other immunosuppressive medications within 14 days prior to enrollment or for the course of the study
Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Having received a live vaccine within 4 weeks prior to the first dose of investigational drug
Having received a live anti-tumor vaccine, or anti-tumor treatment with immunostimulation
Serious medical illness, such as severe infections, uncontrollable diabetes mellitus, cardiovascular diseases (i.e., grade 3 or 4 congestive heart failure (New York Heart Association (NYHA)), grade 2 heart block, myocardial infarction, uncontrolled arrhythmias, or unstable angina within 6 months prior to screening, and cerebral infarction within 3 months prior to screening) or lung diseases (i.e. interstitial pneumonia, obstructive pulmonary disease and symptomatic bronchospasm)
Patients with positive HBsAg and/or positive HBcAb with positive hepatitis B virus DNA> 103 copies/mL, or positive hepatitis C virus antibody; or positive syphilis
A known history of human immunodeficiency virus (HIV) infection, or other acquired and congenital immune deficiency diseases
A known history of active tuberculosis within 1 year prior to the first dose of investigational drug
Presence of other malignant cancers within 5 years prior to enrollment. Patients with cured carcinoma in situ and cured skin basal cell carcinoma or cutaneous squamous cell carcinoma are eligible
Having undergone allogeneic hematopoietic stem cell transplantation or solid organ transplantation
Having undergone major surgery (with the exception of baseline tumor biopsy), or serious trauma within 4 weeks prior to the first dose of therapy
A history of alcoholism or drug abuse within 1 year
A clear history of neurological or mental disorders, i.e. epilepsy, dementia, and poor compliance
Patients with other severe, acute or chronic disease that might increase risk of study drug use and participation, or laboratory abnormality that might confound the results of the trial
Subjects not eligible for the study for other reasons, evaluated by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note